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Objective: Type 2 diabetes mellitus (T2DM) is related to an elevated risk of mild cognitive
impairment (MCI). Plasma clusterin is reported associated with the early pathology
of Alzheimer’s disease (AD) and longitudinal brain atrophy in subjects with MCI. The
rs11136000 single nucleotide polymorphism within the clusterin (CLU) gene is also
associated with the risk of AD. We aimed to investigate the associations among plasma
clusterin, rs11136000 genotype and T2DM-associated MCI.
Methods: A total of 231 T2DM patients, including 126 MCI and 105 cognitively
healthy controls were enrolled in this study. Demographic parameters were collected
and neuropsychological tests were conducted. Plasma clusterin and CLU rs11136000
genotype were examined.
Results: Plasma clusterin was significantly higher in MCI patients than in control group
(p = 0.007). In subjects with MCI, plasma clusterin level was negatively correlated
with Montreal cognitive assessment and auditory verbal learning test_delayed recall
scores (p = 0.027 and p = 0.020, respectively). After adjustment for age, educational
attainment, and gender, carriers of rs11136000 TT genotype demonstrated reduced risk
for MCI compared with the CC genotype carriers (OR = 0.158, 2χ = 4.113, p = 0.043).
Multivariable regression model showed that educational attainment, duration of diabetes,
high-density lipoprotein cholesterol (HDL-c), and plasma clusterin levels are associated
with MCI in T2DM patients.
Conclusions: Plasma clusterin was associated with MCI and may reflect a protective
response in T2DMpatients. TT genotype exhibited a reduced risk of MCI compared to CC
genotype. Further investigations should be conducted to determine the role of clusterin
in cognitive decline.
Trial registration
Advanced Glycation End Products Induced Cognitive Impairment in Diabetes: BDNF
Signal Meditated Hippocampal Neurogenesis ChiCTR-OCC-15006060; http://www.
chictr.org.cn/showproj.aspx?proj=10536
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INTRODUCTION
With the development of living condition and the increased
number of aging population, type 2 diabetes mellitus (T2DM)
is becoming prevalent. According to International Diabetes
Federation atlas, the prevalence of T2DM were 8.8 and 10.6%
in the world and China by 2015, respectively (Available)1.
Diabetes itself and its complications seriously threaten human
health; diabetes-induced lesions in the central nervous system has
increasingly received attention (Van Harten et al., 2006). Studies
have suggested that T2DM patients suffer from mild cognitive
impairment (MCI) (Cukierman et al., 2005; Cheng et al., 2012), a
transitional stage between normal cognitive aging and dementia
(Mariani et al., 2007). A review combined 42 studies showed that
the prevalence of MCI was 3–42% and the incidence of MCI
was 21.5–71.3 per 1000 person-years, respectively (Ward et al.,
2012). The etiology of diabetes-related cognitive impairment is
complicated and associated with many factors, such as insulin
impairment, high oxidative stress, mitochondrial dysfunction,
and dyslipidemia (Ahmad, 2013). However, the underlying
mechanisms remain unclear.
Clusterin, also named apolipoprotein J, is a multifunctional
lipoprotein and exists at high levels in the brain, plasma,
liver, and cerebrospinal fluid (Mullan et al., 2013). This stress-
induced protein is associated with a sort of physiological
functions, including apoptosis, lipid transport, endocrine
secretion, complement regulation, membrane protection, sperm
maturation, and promotion of cell interactions, as well as serves
as complement inhibitor and molecular chaperone (Jones and
Jomary, 2002; Nuutinen et al., 2009). Studies have shown that
clusterin, similar to its predecessor apolipoprotein E (ApoE),
plays a vital role in the pathogenesis of Alzheimer’s disease (AD)
(Sihlbom et al., 2008; Yu and Tan, 2012). In addition, plasma
clusterin is related to brain atrophy, baseline disease severity,
and rapid clinical progression in AD (Thambisetty et al., 2010).
A vitro study has shown that clusterin influences amyloid-beta
(Aβ) clearance (Holtzman, 2004), and enhances Aβ uptake by
adult human astrocytes (Nielsen et al., 2010). Moreover, clusterin
is associated with the early stages of AD pathology (Lidstrom
et al., 1998), and plasma clusterin is related to longitudinal
brain atrophy in MCI patients (Thambisetty et al., 2012). In
T2DM, a significantly increased level of plasma clusterin was
found (Trougakos et al., 2002) and clusterin might be an useful
biomarker for detecting the early stage of diabetic retinopathy
(Jin et al., 2016). Taken together, we hypothesize that plasma
clusterin is related with MCI in T2DM patients.
CLU gene is located on chromosome 8p21 and contains 9
exons. It is suggested that CLU gene is involved in many severe
physiological disease such as diabetes and neuron degeneration
(Trougakos and Gonos, 2006; Meerzaman et al., 2014; Park
et al., 2014). What’s more, CLU is associated with intensified
the deleterious effects of T2DM on neurocognitive slowing
(McFall et al., 2015). Recent genome-wide association studies
have reported that the single nucleotide polymorphism (SNP)
rs11136000 in the CLU gene is associated with late-onset AD
1Available: http://www.diabetesatlas.org/ [Accessed].
(LOAD) among Caucasians (Harold et al., 2009; Lambert et al.,
2009). A reduced risk of LOAD in individuals with TT genotype
than CC genotype was found. CC genotype carriers have
hyperactivation in hippocampus, frontal cortex, and posterior
cingulate cortex compared to TT carriers when performing
working memory task (Ma et al., 2011; Lancaster et al., 2015).
In addition, subjects carried the CC allele exhibited the highest
Aβ deposition than TC and TT allele carriers (Tan et al., 2016).
Consistently, T allele of rs1113600 in CLU gene is associated with
an obviously reduced risk of AD development (Harold et al.,
2009; Lambert et al., 2009), and the C allele expressed a 1.16
greater odds of AD than T allele (Bertram et al., 2007). However,
conflicting results were obtained from Chinese population. Chen
et al have shown that rs11136000 polymorphism is associated
with AD (Chen et al., 2012). By contrast, two studies have found
that rs11136000 is either weakly associated or not associated with
AD (Yu et al., 2010; Ma et al., 2011). In addition, no study has
investigated the association of CLU rs11136000 polymorphism
with diabetes-related MCI.
From the above, potential roles for both clusterin protein
concentration and CLU gene exist in cognitive impairment
pathological process. One possible mechanism for the
relationship may be variant of CLU modifiers of plasma
clusterin expression. A previous study identified 11% higher
level of plasma clusterin in rs11136000 TT carriers than CC
carriers in cognitive healthy individuals (Schurmann et al.,
2011). By contrast, a recent published study found that TT
homozygotes had lower plasma clusterin level compared to
CC homozygotes in subjects with healthy-cognition (Mullan
et al., 2013). Considering the conflicting results and deficient
data in MCI patients, we also explore whether plasma clusterin
concentration is influenced by SNP rs11136000 in CLU gene.
This study aimed to explore the association of plasma
clusterin with cognitive performances, and investigate whether
SNP rs11136000 in CLU gene is related with plasma clusterin
expression and T2DM-associated MCI.
MATERIALS AND METHODS
Study Population
This study was conducted among 231 T2DM patients who were
hospitalized in the Department of Endocrinology at the Affiliated
Zhongda Hospital of Southeast University. The participants were
all Chinese Han, and they provided written informed consent
which is approved by the Research Ethics Committee of the
Affiliated Zhongda Hospital of Southeast University.
We recruited 40–80-year-old patients who can understand
and cooperate with the study procedures. All patients were
diagnosed with T2DM based on the 1999 World Health
Organization criteria (Alberti and Zimmet, 1998). Among the
participants, 126 were diabetic patients with MCI and 105 were
diabetic patients showing healthy cognition. All MCI patients
satisfied the diagnostic criteria proposed by the MCI Working
Group of the European Consortium on AD, as follows: (1)
cognitive complaints from patients or their families; (2) decline
in cognitive function in the past year relative to previous abilities,
as reported by a patient or by an informant (clinical dementia
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rating (CDR) score of 0.5); (3) cognitive disorders as evidenced by
clinical evaluation (impairment in memory or in other cognitive
domain); (4) absence of major limitations in activities of daily
living (ADL) score of 26; and (5) absence of dementia (Portet
et al., 2006). The exclusion criteria were as follows: severe
hypoglycemia, hyperosmolar non-ketotic diabetic coma, diabetic
ketoacidosis, or other acute diabetic complications; history of
stroke, epilepsy, Parkinson’s disease, head injury, central nervous
infection, major depression, or other neurological and psychiatric
diseases; acute cardiovascular disease (CVD), cancer, thyroid
dysfunction, or othermedical illness; auditory or visual disorders;
history of alcohol abuse or drug abuse; and history of medical
drugs that possibly affect or known to affect cognition.
Clinical Data Collection
Demographic variables including ethnicity, age, gender,
occupation, educational attainment, and history of smoking
and drinking, were collected through a standardized interview.
Detailed medical history including duration of diabetes, diabetes
complications, current treatment for diabetes, hypertension
(including treatment), and CVD, were recorded. Weight and
height were used to calculate the body mass index [BMI =
weight/height2 (kg/m2)]. Hypertension was defined as a systolic
blood pressure of ≥140mmHg or a diastolic blood pressure
of ≥90mmHg (Chobanian et al., 2003), or indicated by a
medical history of antihypertensive drugs. Blood samples were
extracted to assess the fasting blood glucose (FBG), glycosylated
hemoglobin (HbA1c), c peptide levels after a standard oral
glucose tolerance test, thyroid stimulating hormone (TSH),
serum creatinine (Scr), blood uric acid, triglyceride (TG), total
cholesterol (TC), low-density lipoprotein cholesterol (LDL-c),
and high-density lipoprotein cholesterol (HDL-c). Estimated
glomerular filtration rate (eGFR) was calculated as follows:
[(140-age)∗weight]∗(0.85 if female)/Scr∗72. All parameters were
measured in the laboratory of ZhongDa Hospital of Southeast
University.
Measurement of Plasma Clusterin
Plasma clusterin levels were measured using enzyme-linked
immunosorbent assay (ELISA) kits (DCLU00, R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. The minimum detectable concentrations of
clusterin was 3.1 ng/ml. Blood samples of all the participants
were measured on the same day.
Neuropsychological Tests
All patients underwent a follow-up neuropsychological tests to
assess their cognitive function including attention, immediate
memory, delayed memory, semantic memory, executive
function, visual–spatial ability, and psychomotor speed:
Montreal cognitive assessment (MoCA), auditory verbal learning
test (AVLT), logic memory test (LMT), complex figure test
(CFT), digit span test (DST), trail making test-A (TMT-A), trail
making test-B (TMT-B), verbal fluency test (VFT), clock drawing
test (CDT). Self-rating depression scale, Hamilton depression
rating scale, Hachinski ischemic scale, ADL scale, and CDR
scale were also used. An experienced neuropsychiatrist from
the Department of Neurology, Affiliated ZhongDa Hospital of
Southeast University performed all the tests.
Genotyping of CLU rs11136000
Polymorphism
DNA was extracted from venous blood by using a DNA
purification kit (158389, Puregene, GentraSystem, Minneapolis,
MN) according to the manufacturer’s instruction. Polymerase
chain reaction (PCR) was performed to amplify the CLU
gene (rs11136000) by using the upstream primer 5′-
GTGCCTACCCTTGCTCCA-3′ and the downstream primer
5′-TCACTACAACCTCCGCCTC-3′. PCR was performed in
30µL reactions containing 20.8µL of ddH2O, 3.0µL of 10
× PCR buffer, 2µL of DNA, 1µL of primer forward, 1µL of
primer reverse, 2µL of dNTP, and 0.2µL of Ex Taq. The PCR
conditions were as follows: preliminary denaturation at 96◦C
for 5min followed by 30 cycles of denaturation at 96◦C for 20 s,
annealing at 62◦C for 20 s, and extension at 72◦C for 30 s, with a
final extension step at 72◦C for 10min. The PCR products were
electrophoresed on 2.0% agarose gel.
Statistical Analysis
Data were expressed as mean±standard deviation, median
(interquartile range), or percentage. Normally distributed
variables were analyzed by Student’s t-test and ANOVA,
whereas asymmetrically distributed variables were analyzed
using non-parametric Mann−Whitney U and Kruskal−Wallis
tests. The Chi-squared test was conducted to compare non-
continuous variables and analyzed Hardy-Weinberg equilibrium
of the distributions of genotype and allele frequencies. Partial
correlation was used to evaluate the relationships between
neuropsychological test scores and plasma clusterin. Simple
logistic regression model was first performed to select
independent factors that increase the selection risk of MCI
in T2DM patients. Multivariable regression was subsequently
used to investigate the “strongest” factor among the independent
risk factors for MCI in T2DM patients. Odds ratios (ORs) and
95% confidence interval (CI) were presented after adjusted
for the significant covariates, such as age, education and
gender. Statistical analyses were performed using SPSS 20.0
(IBM Corporation). A p-value of < 0.05 indicated statistical
significance.
RESULTS
Demographic, Clinical, and Cognitive
Characteristics
Table 1 shows the baseline characteristics of the recruited
patients. Among the enrolled T2DM patients, 126 exhibited
MCI and 105 showed healthy cognition. Compared with the
diabetic patients with healthy cognition, the diabetic patients
with MCI were older, attained lower education levels, have
been suffering from diabetes for a longer period, and a greater
fraction of them were diagnosed with CVD. Patients with
MCI displayed a significantly higher level of HbA1c and
lower level of HDL-c than the control group. No significant
differences between two groups were found regarding gender,
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TABLE 1 | Demographic, clinical and cognitive characteristics of type 2 diabetic patients.
Characteristic MCI group (n = 126) Control group (n = 105) p-value
Age (years)* 62.56 ± 8.53 58.71 ± 7.97 <0.001
Gender (female/male) 60/66 41/64 0.191
Educational attainment (years)* 9.00 (6.00–12.00) 10.00 (9.00–13.00) <0.001
Ever smoked, n (%) 53 (42.06) 48 (45.71) 0.578
Drinking, n (%) 35 (27.78) 26 (24.76) 0.605
BMI (kg/m2) 25.17 ± 3.53 24.99 ± 3.37 0.696
Hypertension, n (%) 82 (65.08) 63 (60.00) 0.427
SBP (mmHg) 138.00 (122.00–148.00) 130.00 (124.00–140.00) 0.208
DBP (mmHg) 80.00 (75.00–90.00) 80.00 (75.00–90.00) 0.654
Diabetes duration (years)* 10.67 ± 6.12 8.95 ± 4.99 0.022
HbA1c (%)* 9.50 ± 2.15 8.90 ± 2.32 0.042
FBG (mmol/L) 8.20 ± 2.84 7.75 ± 2.67 0.228
Fasting C peptide (ng/mL) 1.96 ± 2.37 1.72 ± 1.06 0.377
C peptide (120min) 4.93 ± 2.85 4.97 ± 2.93 0.936
TG (mmol/L) 1.67 (1.13–2.44) 1.49 (1.13–2.50) 0.666
TC (mmol/L) 4.92 ± 1.56 4.88 ± 1.24 0.855
LDL- c (mmol/L) 2.91 ± 0.89 2.97 ± 0.87 0.627
HDL- c (mmol/L)* 1.18 ± 0.30 1.26 ± 0.24 0.030
Serum creatinine (umol/L) 71.50 ± 21.48 74.47 ± 19.75 0.309
eGFR (mL/min per 1.73 m2 ) 91.67 ± 36.06 93.48 ± 31.48 0.706
Blood uric acid (umol/L) 285.84 ± 93.13 282.62 ± 83.09 0.796
TSH (uul/mL) 2.12 (1.24–3.06) 1.94 (1.33–3.58) 0.757
Coronary heart disease (%)* 40 (31.75) 21 (20.00) 0.044
Diabetic nephropathy (%) 34 (26.98) 22 (20.95) 0.287
Neuropathy (%) 26 (20.63) 20 (19.05) 0.764
Clusterin (ug/ml)* 115.67 ± 31.59 104.24 ± 32.01 0.007
Use of insulin (%) 86 (68.25) 70 (66.67) 0.798
Oral hypoglycemic drugs (%) 104 (82.54) 82 (78.10) 0.396
Antihypertensive medications (%) 72 (57.14) 47 (44.76) 0.061
COGNITION TEST LEVELS
MoCA* 21.00 (17.75–23.00) 27.00 (26.00–28.00) <0.001
AVLT _IR* 15.68 ± 4.46 20.12 ± 4.57 <0.001
AVLT_DR* 4.54 ± 2.23 7.09 ± 2.53 <0.001
LMT_IR* 5.79 ± 3.94 10.16 ± 4.16 <0.001
LMT_DR* 4.68 ± 3.58 8.11 ± 3.74 <0.001
CFT_DR* 8.00 (7.00–9.00) 16.00 (14.00–18.00) <0.001
DST* 11.00 (8.00–12.00) 12.00 (11.00–14.00) <0.001
TMT-A* 83.00 (60.00–110.00) 58.00 (48.00–70.50) <0.001
TMT-B* 198.00 (150.00–277.00) 143.00 (111.50–179.50) <0.001
VFT* 15.14 ± 3.94 17.50 ± 4.03 <0.001
CDT* 3.00 (2.00–4.00) 4.00 (4.00–4.00) <0.001
*Significance, p < 0.05; comparing patients with MCI and those without MCI (controls). Data are presented as n (%), mean ± SD, or median (interquartile range) as appropriate.
Student’s t test, Mann-Whitney U test, or χ2 test was used to test for significant differences. Abbreviations: MCI, mild cognitive impairment; BMI, body mass index; SBP, systolic blood
pressure; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; FBG, fasting blood-glucose; TG, triglyceride; TC, total cholesterol; LDL-c, low density lipoprotein cholesterol;
HDL-c, high density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; TSH, thyroid stimulating hormone; MoCA, Montreal Cognitive Assessment; AVLT_IR, auditory
verbal learning test, immediately recall; AVLT_DR, auditory verbal learning test, delayed recall; LMT_IR, logic memory test, delayed recall; LMT_DR, logic memory test, delayed recall;
CFT_DR, complex figure test, delayed recall; DST, Digit Span Test; TMT-A, Trail Making Test-A; TMT-B, Trail Making Test-B; VFT, Verbal Fluency Test; CDT, Clock Drawing Test.
BMI, history of smoking and drinking, blood pressure, FBG,
C peptide, TG, TC, LDL-c, Scr, blood uric acid, TSH levels,
presence of neuropathy, diabetic nephropathy, and treatment
with insulin, oral hypoglycemic drugs, and antihypertensive
medications (all p > 0.05). Compared with the control
group, the MCI group showed a significantly higher level of
plasma clusterin (104.24 ± 32.01 vs. 115.67 ± 31.59 ug/ml,
p = 0.007). Neuropsychological test scores were significantly
lower in the MCI group than in the non-MCI group (p <
0.05).
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TABLE 2 | Partial correlations of plasma clusterin concentrations with
neuropsychological tests in T2DM patients with MCI.
Control variables r p-value
MoCA* Age, educational attainment, and gender −0.302 0.027
AVLT _IR −0.253 0.065
AVLT_DR* −0.315 0.020
LMT_IR −0.084 0.547
LMT_DR −0.079 0.569
CFT_DR −0.054 0.701
DST 0.129 0.352
TMT-A 0.037 0.793
TMT-B 0.064 0.643
VFT −0.105 0.451
CDT −0.046 0.742
*Significance, p < 0.05. Partial correlation was used. Abbreviations: T2DM, type
2 diabetes mellitus; MCI, mild cognitive impairment; MoCA, Montreal Cognitive
Assessment; AVLT_IR, auditory verbal learning test, immediately recall; AVLT_DR, auditory
verbal learning test, delayed recall; LMT_IR, logic memory test, delayed recall; LMT_DR,
logic memory test, delayed recall; CFT_DR, complex figure test, delayed recall; DST, Digit
Span Test; TMT-A, Trail Making Test-A; TMT-B, Trail Making Test-B; VFT, Verbal Fluency
Test; CDT, Clock Drawing Test.
Relationship between Cognitive
Performances and Plasma Clusterin
Given that significant differences between two groups were
observed in terms of neuropsychological test scores and plasma
clusterin, partial correlations between neuropsychological test
scores and plasma clusterin were conducted. The results showed
that plasma clusterin level was negatively correlated with MoCA
score and AVLT-delayed recall in theMCI subgroup (r= −0.302,
p = 0.027; and r = −0.315, p = 0.020, respectively)
after adjusting the age, educational attainment, and gender. No
significant correlations between LMT_IR, LMT_DR, CFT_DR,
DST, TMT-A, TMT-B, VFT, or CDT and plasma clusterin were
found (p > 0.05; Table 2).
Distributions of CLU Genotype and Allele
Frequencies in MCI and Non-MCI Groups
Table 3 shows the distributions of CLU genotype and allele
frequencies in the two groups. The CLU genotype was consistent
with Hardy Weinberg equilibrium in non-MCI group (χ2 = 0,
df = 1, p > 0.05) and MCI group (χ2 = 0.93, df = 1, p > 0.05).
In addition, no differences were observed between the two groups
in terms of distributions of CLU genotype (χ2 = 2.709, df = 2,
p = 0.258) and allele (OR= 0.713, χ2 = 2.038, p = 0.153). With
CC genotype as reference, the OR of genotype TT was 0.158 (OR
= 0.158, χ2 = 4.113, p = 0.043) after adjustment for age, gender,
and educational attainment.
Comparison of Plasma Clusterin and
Cognitive Performances between Different
CLU Genotypes
No significant differences in plasma clusterin levels were
observed among the CLU genotypic subgroups (CC, CT, and
TT) in either MCI or non-MCI group (p > 0.05; Table 4).
In addition, no significant differences were identified between
genotypic subgroups in terms of neuropsychological test scores
in either MCI or control groups (p > 0.05; Table 5).
Logistic Regression Models
To investigate the risk factors of MCI in T2DM, we conducted
univariate logistic regressions to select the so-called independent
variables for multivariable regression model. The independent
variables used in the simple logistic regression model include age,
gender, educational attainment, history of smoking and drinking,
duration of diabetes, FBG, HbA1c, fasting C peptide, C peptide
(120min), TG, TC, LDL-c, HDL-c, serum creatinine, eGFR,
blood uric acid, TSH, SBP, DBP, prevalence of hypertension,
CVD, diabetic nephropathy, neuropathy, plasma clusterin level
and CLU genotype. The results showed that the variables
associated with MCI in T2DM diabetes include old age, low
education levels, long duration of diabetes, low HDL-c level,
CVD history, and high HbA1c and clusterin levels (Table 6).
Multivariable regression revealed that educational attainment,
duration of diabetes, and HDL-c and clusterin levels are
associated with MCI in T2DM patients (Table 7).
DISCUSSION
Our study suggested that plasma clusterin concentration
increased and was negatively correlated with memory
performance in T2DM patients with MCI. TT genotype carriers
demonstrated a reduced MCI risk compared with CC genotype
carriers after adjustment for age, educational attainment,
and gender. High clusterin level, low HDL-c concentration,
long duration of diabetes, and low educational attainment
are associated with MCI in T2DM patients. No significant
differences in plasma clusterin levels or neuropsychological test
scores were observed among CLU genotypes either in MCI or
control groups.
Consistent with previous results (Thambisetty et al., 2012;
Mullan et al., 2013; Jongbloed et al., 2015), plasma clusterin
level was higher in MCI patients than in cognitively healthy
group. Similar results were observed in studies that compared
AD patients with control participants (Schrijvers et al., 2011;
Xing et al., 2012; Mullan et al., 2013). However, in contrast to
our result, some studies have found that plasma clusterin levels
were not increased in patients with presymptomatic AD or in
individuals who later developed AD or in AD patients, compared
with individuals who remained cognitively healthy (IJsselstijn
et al., 2011; Silajdzic et al., 2012; Jongbloed et al., 2015). This
disparity may be attributed to the difference in study populations
(MCI or AD). One plausible explanation is that in the early
stage, a glial cell and Aβ driven pro inflammatory response
extends from central (AD-affected areas) to the periphery,
leading to the clusterin upregulation in AD affected areas, as
same as in periphery (May et al., 1990; Lidstrom et al., 1998).
In the subsequent stage, the inflammatory response, which
involves microglial activation and cytokine release, subsides
(Eikelenboom et al., 2012), making plasma clusterin levels to drop
to control levels in AD. Another possible interpretation is that
increased plasma clusterin level is related to a reduced rate of
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TABLE 3 | Distributions of CLU genotype and allele frequencies between groups.
CLU genotype MCI, n (%) Non-MCI, n (%) Crude OR (95% CI) p-value Adjusted OR (95% CI)b p-value
Overall 126 105
C 210 (83.33) 164 (78.10) 1.000
T 42 (16.67) 46 (21.90) 0.713 (0.448–1.136) 0.153
CC 86 (68.25) 64 (60.95) 1.000
CT 38 (30.16) 36 (34.29) 0.786 (0.449–1.374) 0.397 0.662 (0.358–1.226) 0.190
TT 2 (1.59) 5 (4.76) 0.298 (0.056–1.584) 0.267a 0.158 (0.027–0.941) 0.043*
CT+TT 40 (31.75) 41 (39.05) 0.726 (0.422–1.249) 0.247 0.588 (0.323–1.071) 0.083
*Significance, p < 0.05. Data are presented as n (%). The genotype and allele frequencies were compared between the groups with Pearson‘s χ2 tests except for the cases labeled
with a, in which the frequency was determined by continuity-corrected Pearson‘s χ2 tests. bAdjusted for age, educational attainment, gender. Abbreviations: CLU, clusterin; MCI, mild
cognitive impairment.
TABLE 4 | The plasma levels of clusterin (ug/ml) in T2DM patients with
MCI or normal cognition.
Genotype
Group CC CT TT p-value
Non-MCI 104.04±35.96 103.97±24.88 108.87±28.78 0.948
MCI 114.66±31.91 117.23±31.87 129.72±5.02 0.753
Total 110.13±33.99 110.78±29.26 114.82±25.69 0.928
Data are presented as mean ± SD. One-way ANOVA for the comparison of the plasma
level of clusterin among different genotypes. Abbreviations: T2DM, type 2 diabetes
mellitus; MCI, mild cognitive impairment.
atrophy as a protective factor in cognitive impairment patients
(Malkki, 2014). However, in established AD subjects, reduced
plasma clusterin level may reflect exhaustion of such protective
mechanisms caused by genetic and/or infaust environmental
effects (Thambisetty et al., 2012). Thus, whether plasma clusterin
serves as a deleterious substance or reflects a neuroprotective
response during progress of cognitive impairment warrants
further research.
Our results showed that plasma clusterin was correlated with
MoCA scores in MCI patients, similar to findings of Meng et al.
(2015) and Schrijvers et al. (2011), who studied MCI patients
and AD patients, respectively. MoCA is a highly sensitive tool
to distinguish MCI from cognitively healthy T2DM patients
(Alagiakrishnan et al., 2013). In addition, plasma clusterin in
MCI patients was associated with AVLT-delayed recall, which
evaluates episodic memory function. Impairment in episodic
memory function is the earliest change in presymptomatic stages
of AD (Grober et al., 2008). Our results were consistent with
the finding that plasma clusterin reflects cognitive function
in MCI patients (Meng et al., 2015) and predicts increased
entorhinal cortex amyloid burden, which is important inmemory
formation (Thambisetty et al., 2010). Several characteristic
properties of clusterin make it related with the pathology of
cognitive impairment. First, clusterin inhibits amyloid formation
by binding Aβ and preventing their aggregation (Desikan et al.,
2014). Second, clusterin is involved in the clearance of Aβ by
enhancing endocytosis in glial cells (Tanzi et al., 2004; Wang
et al., 2006) and by assisting in Aβ transport through the
blood-brain barrier (Zlokovic et al., 1994; Zlokovic, 2004). Third,
clusterin may increase cholesterol transport in conjunction
with ApoE in blood vessels (Gelissen et al., 1998). Fourth,
clusterin can inhibit the activation of complement (Calero et al.,
1999). What’s more, being a chaperone, clusterin can bind to
Smad2/3 proteins to enhance neuroprotective TGFβ signaling
(Lee et al., 2008). In addition, clusterin can be conveyed into
the cytoplasm to bind to Bax protein and suppress neuronal
apoptosis (Nuutinen et al., 2009). These lines of evidence
demonstrated that neurodegenerative changes during cognitive
impairment may increase clusterin expression (Nuutinen et al.,
2009), suggesting the beneficial role of clusterin in AD pathology.
Compared with the studies indicating that the
rs1113600minor T allele occurs less frequently in AD patients
than in cognitively healthy control patients and that CLU
rs11136000 CC genotype is a the risk factor for AD (Bertram
et al., 2007; Carrasquillo et al., 2015), our study found no
difference in the distribution of genotype and allele frequencies
of CLU rs11136000 in T2DM patients with MCI and controls,
possibly because of the low minor allele frequency in Chinese
and the small sample size. However, after adjustment for age,
educational attainment, and gender, our data showed that
compared with the CC genotype, the TT genotype is associated
with reduced risk for T2DM-related MCI, validating the finding
that protective association existed between T allele or TT
genotype and AD (Harold et al., 2009; Lambert et al., 2009). The
following mechanisms may explain a high risk of MCI happened
in CC carriers compared with CT/TT genotype carriers.
Compared to TT/CT genotype, enhanced effects on midline
default mode network (DMN) in CC genotype was found in
MCI subjects (Bai et al., 2016). Midline DMN regions may have
an information-bridging role to task-positive networks (Elton
and Gao, 2015) which is activated when the brain processes
externally presented information (Kim et al., 2010). What’s
more, CC genotype may initially influence restingstate networks
integrity and then lead to cognitive impairment (Bai et al., 2016).
On the other hand, CC genotype was associated with increased
alpha3 absolute power and changes of alpha1 activity in
topographical distribution. The increased synchronization
of upper alpha activity are considered to be associated
with the changes in cortical networks and hippocampal
(Ponomareva et al., 2013). In addition, CC genotype carriers
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TABLE 6 | Assessment results of the risk of having MCI in a simple logistic
regression model in T2DM patients.
B SE p-value
Age (years)* −0.056 0.017 0.001
Gender (female/male) −0.350 0.268 0.192
Educational attainment (years)* 0.185 0.040 <0.001
Ever smoked, n (%) 0.148 0.266 0.578
Drinking, n (%) −0.156 0.301 0.605
BMI (kg/m2) −0.015 0.038 0.694
Hypertension, n (%) −0.204 0.107 0.055
SBP (mmHg) −0.013 0.008 0.124
DBP (mmHg) −0.012 0.013 0.347
Diabetes duration (years)* −0.055 0.024 0.023
HbA1c (%)* −0.123 0.061 0.044
FBG (mmol/L) −0.061 0.050 0.228
Fasting C peptide (ng/mL) −0.081 0.097 0.400
C peptide (120min) 0.004 0.055 0.935
TG (mmol/L) −0.036 0.077 0.635
TC (mmol/L) −0.017 0.094 0.854
LDL-c (mmol/L) 0.074 0.152 0.625
HDL-c (mmol/L)* 1.053 0.492 0.032
Serum creatinine (umol/L) 0.007 0.007 0.308
eGFR (mL/min per 1.73 m2) 0.002 0.004 0.705
Blood uric acid (umol/L) 0.000 0.002 0.795
TSH (uul/mL) −0.034 0.075 0.655
Coronary heart disease (%)* −0.621 0.310 0.045
Diabetic nephropathy (%) −0.332 0.313 0.288
Neuropathy (%) −0.100 0.332 0.716
Clusterin (ug/ml)* −0.012 0.004 0.008
CLU genotype 0.354 0.244 0.147
*Significance, p < 0.05. Abbreviations: MCI, mild cognitive impairment; T2DM, type 2
diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HbA1c, glycosylated hemoglobin; FBG, fasting blood-glucose; TG,
triglyceride; TC, total cholesterol; LDL-c, low density lipoprotein cholesterol; HDL-c, high
density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; TSH, thyroid
stimulating hormone; CLU, clusterin.
may be associated with beta amyloid deposition than TT
genotype carriers (Tan et al., 2016). Despite above-mentioned
explanations, the underlying mechanisms are not fully
understood.
In this study, rs11136000 genotypes exerted no significant
effect on plasma clusterin level in the MCI group, in the
control group, or in both, consistent with previous finding
showed that no effect of polymorphisms in rs11136000 on
plasma clusterin among AD, MCI, and control subjects analyzed
together in white Europeans from United Kingdom, France,
Italy, Finland, Poland, and Greece (Thambisetty et al., 2010).
By contrast, in the study conducted in Germany, an increased
level of plasma clusterin in rs11136000 TT carriers than CC
carriers in cognitive healthy individuals, while no difference
was observed in AD patients (Schurmann et al., 2011). In
Northern Ireland population, researchers found lower plasma
clusterin level in TT homozygotes in subjects with healthy-
cognition (Mullan et al., 2013), while genotype at this SNP
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TABLE 7 | Assessment results of the risk of having MCI in a multivariable
logistic regression model in patients with T2DM.
B SE p-value
Educational attainment (years)* 0.189 0.041 <0.001
Diabetes duration (years)* −0.059 0.026 0.024
HDL- c (mmol/L)* 1.189 0.545 0.029
Clusterin (ug/ml)* −0.011 0.005 0.019
*Significance, p < 0.05. Abbreviations: MCI, mild cognitive impairment; T2DM, type 2
diabetes mellitus; HDL-c, high density lipoprotein cholesterol.
showed no influence on plasma clusterin when control, MCI
and AD individuals were analyzed together. The following
factors may explain the conflicting findings. Disease-related
increases of plasma clusterin covered the effect of genotype
on clusterin protein, so change of plasma clusterin level only
observed in the control group and not in groups analyzed
together. Another interpretation is that the association between
plasma clusterin and AD pathological processes is probably
independent of genetic variation (Thambisetty et al., 2010) or
rs11136000 may not be the clusterin SNP that induces expression
or functional changes in clusterin protein. Thus, larger sample
size studies combining analysis of clusterin protein concentration
and CLU gene variation are needed to validate this finding.
In addition, our data suggested that no significant relationship
exists between rs11136000 polymorphism of the CLU gene and
the cognitive performance domains, such as executive function
and memory performance. In contrast to our results, a previous
study has found high and low memory scores in individuals with
protective and risk alleles of CLU rs11136000 SNP, respectively
(Thambisetty et al., 2013; Pedraza et al., 2014). Several conditions
may explain this difference. First, the participants in the current
study are Chinese Han patients, which are different from the
Caucasian population (Thambisetty et al., 2013; Pedraza et al.,
2014). Second, cognitive impairment during AD progression is
complicated and affected by several genes (Cox et al., 2014);
rs11136000 polymorphism may have only exerted a slight
influence. Third, mutual effects of gene and environment should
have been considered (Rajan et al., 2014). Despite all these factors,
we believe that an underlying association exists between memory
decline and CLU gene, considering that a recent study has
found that neural hyperactivation occurred in the frontal cortex,
posterior cingulate cortex, and hippocampus during a working
memory task in healthy young adults carry AD risk variant in
CLU (Lancaster et al., 2011).
In our study, multivariable logistic regression model shows
that educational attainment, duration of diabetes, low HDL-
C, as well as clusterin are associated with MCI in diabetic
patients. Except that people with higher education have less
chance to develop MCI, study also suggested that high education
was a protective factor for the conversion from MCI to AD
(Tervo et al., 2004). However, the underlying mechanism needs
further investigation. There is a growing awareness that patients
with longer diabetes duration had severe condition of oxidative
stress (Polidori et al., 2000). Oxidative stress plays an important
role in the development of atherosclerosis as well as cognitive
impairment in T2DM (Mackness et al., 1997; Ahmad, 2013).
Scholars have found that clusterin was accumulated in the artery
wall to protect against the oxidative stress (Mackness et al.,
1997). For the same reason, elevated plasma clusterin may also
represent a protective mechanism against cognitive impairment
in response to oxidative stress that caused by longer diabetes
duration (Thambisetty et al., 2012). In plasma, an important
source of clusterin is associated with HDL particles (Calero et al.,
1999). Several studies in different populations have suggested that
high HDL-c levels were associated with a reduced risk for AD
(Launer et al., 2001; Reitz et al., 2004; Vollbach et al., 2005).
Another study has found a strong positive correlation between
clusterin levels in HDL and insulin sensitivity which is important
during pathology of diabetes-associated MCI (Hoofnagle et al.,
2010; Roberts et al., 2014). Thus, we speculate that increased
plasma clusterin possibly plays a protective role in the early
stage of AD. It is worth noting that we identified no different
prevalence of MCI between man and women. Also, gender is
not the independent factor that influence the likely of having
MCI in T2DM patients. Other studies have found a similar
result although different methods of diagnostic criteria for MCI
were used (Hanninen et al., 2002; Solfrizzi et al., 2004). On the
contrary, either a higher prevalence of MCI in men than women
(Ganguli et al., 2004; Petersen et al., 2010) or a higher prevalence
of MCI in women compared with men were observed in different
population (Larrieu et al., 2002; Di Carlo et al., 2007). Except
for the difference of ethnicity, we consider the diabetic status
of subjects in this study increase the prevalence of MCI that
narrowed the gap between men and women.
This study provides significant insights into plasma clusterin
and CLU rs11136000 polymorphism underlying MCI in T2DM
patients. However, certain limitations should not be ignored.
First, the sample size was relatively small and thus, results of
this study should be interpreted carefully. Second, the study was
not a longitudinal prospective research; AD patients were not
included in this study and thus we could not clarify the clusterin
variation during AD progression; therefore, we cannot determine
whether plasma clusterin is a preclinical marker of AD. Third,
magnetic resonance imaging was not performed in this study, so
brain pathologic change of cognitive impairment under the state
of T2DM is unclear.
CONCLUSION
In summary, our data showed that plasma clusterin is increased
in T2DM patients with MCI, compared with cognitively healthy
controls. CLU rs11136000 TT genotype is associated with
a reduced MCI risk compared with the CC genotype after
adjustment for age, educational attainment, and gender. Elevated
plasma clusterin levels may reflect a neuroprotective response in
T2DM patients with MCI. Further studies need to be conducted
to determine whether clusterin can be used as an underlying
early marker of diabetes-associated MCI; in addition, studies
with a larger sample-size should be performed to investigate
the association between rs11136000 polymorphism and MCI
in T2DM. As an option, interventions that stimulate clusterin
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expression probably result in a beneficial effect for subjects with
cognitive decline.
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